Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
NBIX
NBIX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NBIX News
Neurocrine Shares Drop 8% After Mixed Earnings Despite Strong Ingrezza Sales
2d ago
Newsfilter
Neurocrine Reports Q4 Earnings Miss Amid Strong Sales Growth
2d ago
Benzinga
Wall Street Analysts Adjust Ratings
3d ago
Benzinga
Neurocrine Biosciences Q4 2025 Earnings Call Highlights
3d ago
seekingalpha
Neurocrine Biosciences Q4 Earnings Analysis
3d ago
seekingalpha
Neurocrine Biosciences Reports Strong 2025 Financial Results
3d ago
Yahoo Finance
Neurocrine Biosciences Q4 Earnings Announcement Scheduled
4d ago
seekingalpha
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
Jan 26 2026
PRnewswire
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
Jan 26 2026
Newsfilter
Neurocrine Biosciences Presents Head-to-Head Data Showing INGREZZA's Superior VMAT2 Target Occupancy Over AUSTEDO XR
Jan 15 2026
PRnewswire
Neurocrine Biosciences Presents Head-to-Head VMAT2 Occupancy Data for INGREZZA vs AUSTEDO XR, Showing Nearly Double Potency
Jan 15 2026
Newsfilter
AbbVie Upgraded Price Target to $269 Despite 4% Stock Drop
Jan 06 2026
Benzinga
Crinetics Pharmaceuticals Reports Significant Results in CAH Study with Atumelnant
Jan 05 2026
Benzinga
Neurocrine Biosciences Reports Phase 3 KINECT-DCP Study Results, Misses Key Endpoints
Dec 23 2025
Benzinga
Neurocrine Biosciences Fails to Meet Primary Endpoints in KINECT-DCP Study
Dec 23 2025
NASDAQ.COM
Neurocrine Biosciences Fails to Meet Key Endpoints in Phase 3 KINECT-DCP Study
Dec 22 2025
PRnewswire
Show More News
